BioIVT

Even after stroke treatment, patients remain at risk for serious complications, such as post-thrombectomy intracranial hemorrhages (PTIH), making close monitoring essential. In #neurology, understanding why some patients experience these complications while others don’t remain one of the field’s most pressing challenges. This 2023 study in Frontiers in Neurology identified S100b, a protein found in acute ischemic stroke clots, as a potential biomarker for predicting post-thrombectomy intracranial hemorrhage risk. This type of #BiomarkerResearch, powered by high-quality #biospecimens, is helping shift stroke care from reactive intervention to more predictive, personalized monitoring. https://hubs.ly/Q04gZDXf0 BioIVT is proud to have provided the entorhinal cortical brain tissue used as positive control for S100b expression. Explore our related CNS specimens: https://hubs.ly/Q04g-0ZJ0

Check out our new Events Newsletter for more great in-person and online events where you can interact with our experts and see numerous insightful presentations including:  • Therapeutic reversal of established #steatosis using siRNA in HEPATOPAC  • In vitro and in vivo #LiverDisease models (roundtable)  • Donor profiling strategies and isolation techniques to enable scalable #CGT manufacturing  • Beyond CYP: In vitro tools for exploring tissue metabolism - a #GLP1 peptide drug case study  • Mechanism, ADME challenges and translational strategies for #ProteinDegraders  • Alterations in CYP2B6.6 vs. CYP2B6.1 activity are #substrate dependent  • And more! ⬇️

#ProteinDegraders are opening new doors in drug discovery, but also raising important scientific questions about how we evaluate these molecules with their unique physicochemical properties and mechanisms of action in preclinical development. So where do things stand today? And where are we headed? 🔬 Current landscape: #MolecularGlues thalidomide, lenalidomide, and pomalidomide were approved under small molecule regulatory frameworks. Heterobifunctional #degraders will likely be evaluated through that same lens, requiring standard in vitro #ADME studies. 📈 What’s next: The field is rapidly evolving with the first #PROTAC (Vepannu) having just received FDA approval for patients with ER-positive, HER2-negative advanced or metastatic breast cancer. At the same time, research is expanding beyond oncology into neurodegenerative and immunological diseases, and exploring new ligases to enable more precise, tissue-specific targeting and expand the pool of potential POIs. As protein degraders continue to advance, aligning preclinical strategies with both current requirements and future regulatory direction will be critical. Learn more in a June 24 webinar with Tina Mueller, PhD entitled “Protein Degraders in Drug Discovery: Mechanism, ADME Challenges, and Translational Strategies”: https://hubs.ly/Q04g-1y40

If you’re working with disease state biofluids, normal biofluids are often part of the workflow. Across diagnostics, drug development, and liquid biopsy programs, normal biofluids are used to establish biological baselines, support assay validation, and help ensure disease state data can be interpreted with confidence. What many teams may not know is that BioIVT supplies high quality normal human and animal biofluids alongside the disease state materials they already source from us. By supporting both normal and disease state biofluids, BioIVT helps teams simplify sourcing while maintaining consistent quality and documentation across studies. 👉 Learn more about BioIVT’s normal biofluids: https://hubs.ly/Q04h6mJs0

Join Courtney Noah, PhD and William Lloyd, PhD, CPI with Akadeum Life Sciences, Inc. for a webinar outlining donor profiling strategies and isolation techniques to enable scalable #CellandGeneTherapy manufacturing. Key discussion points include: ➡️ Sourcing phenotyped donor material ➡️ Profiling HLA diversity to inform experimental design ➡️ Preserving natural cell biology with negative selection ➡️ Manufacturing high-viability cells with preserved memory phenotypes Learn more and register: https://hubs.ly/Q04gZBnc0

The future of #cancer care depends on detecting what matters earlier, more accurately, and less invasively. #LiquidBiopsy is transforming how cancer is detected and monitored, offering a less invasive, more dynamic view of disease. But the promise of this approach depends on the quality and context of the human #biospecimens behind the data. Cell-free DNA, circulating tumor cells, and exosomes can unlock powerful insights, but only when studied using well-characterized, clinically relevant samples. High-quality biospecimens, paired with robust #clinicaldata, are what enable researchers to distinguish true signals from noise and move discoveries toward real-world impact. BioIVT’s biospecimen portfolio is designed to support the full continuum of #biomarker discovery and liquid biopsy enablement from early exploration to validation, helping researchers generate data that is both accurate and translatable. Read the full blog about the importance of human biospecimens in liquid biopsy research: https://hubs.ly/Q04gZXy60 Explore BioIVT’s Biomarker Discovery offerings: https://hubs.ly/Q04gZXdB0

#LiquidBiopsy is rapidly evolving beyond early cancer detection alone. As clinical biomarkers and companion diagnostics become more integrated into precision medicine, the demands around sensitivity, specificity, and translational relevance continue to grow. What was once considered an emerging technology is now helping shape how disease is monitored, therapies are selected, and treatment response is evaluated. And as the field continues to advance, operational confidence is going to be the defining key to shaping clinical action. Read more about the current state of liquid biopsy, biomarkers, and diagnostics: https://lnkd.in/ekXqX-af

The success of #NewApproachMethodologies (#NAMs) often depends on the biological materials that serve as their starting materials. Primary human cells, tissues, and biofluids provide the biological foundation for organoids, microphysiological systems, and other advanced in vitro models, so variability in donor characteristics, tissue integrity, metabolic activity, and cellular composition can significantly influence experimental outcomes. In our new blog, we discuss aligning experimental systems with the biology they are intended to represent and the decisions they are meant to inform – read now: https://hubs.ly/Q04gZH4t0

This year at the #MPSWorldSummit, we will be presenting the #ScientificPoster "Therapeutic reversal of established #steatosis using GalNAc PNPLA3 siRNA in the HEPATOPAC long-term hepatic co-culture system." Metabolic dysfunction associated steatotic liver disease (#MASLD) remains a major unmet need, with limited therapeutic options to reverse established hepatic lipid accumulation. Genetic variation in PNPLA3, particularly the I148M variant, is strongly associated with increased disease susceptibility and persistence of steatosis. The poster demonstrates the use of long-term micropatterned primary human hepatocyte co cultures to evaluate #PNPLA3 knockdown using two #siRNA delivery approaches for genotype-informed target validation and for translational evaluation of #RNAi based therapeutics. Christian Smith will be presenting the poster during the Thursday, 28 May morning session from 10:00-11:30, and make sure to stop by booth #115 to meet with our expert team to discuss your biospecimen and ADME research service questions and needs. Learn more and schedule a meeting with the team: https://hubs.ly/Q04gZVxM0 #MPS2026

Although there is currently no complete cure for #CysticFibrosis, treatments like CFTR modulators can manage symptoms by addressing the defective protein. BioIVT is proud to support research into treating this genetic disorder. For a recent customer study published in the Journal of Medicinal Chemistry on the “Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector,” we provided hepatocytes, microsomes and plasma for their ADME studies: https://hubs.ly/Q04g7db00 We also provide donor-derived PBMCs, bronchial epithelial cells, and other biospecimens as well as a variety of research services to aid in the advancement of next-generation therapies and multi-drug combinations. These combinations, tailored to specific mutations, have the potential to deliver #PrecisionMedicine and improve outcomes, even for patients already on existing therapies. Learn more about our products and services to support your research: https://hubs.ly/Q04g7hXP0